Kunming Biomed International (KBI) is a leading Contract Research Organization (CRO) providing high-quality services for new drug discovery and development with nonhuman primate (NHP) animal models. We are dedicated to improving the healthcare by translating innovative therapeutics to clinical applications through our evaluation in NHP disease models. KBI operates an AAALAC-accredited vivarium with state-of-the-art research facilities and extensive colonies of SPF and purpose-bred NHPs. We conduct studies in pharmacokinetics/ pharmacodynamics (PK/PD), pathology, and exploratory toxicology, utilizing only purpose-bred NHPs. Our research adheres to industry standards, ensuring the highest quality and upholding the utmost ethical standards for animal care and welfare.